Cost Effectiveness Analysis of Combined Anti-Retroviral Therapy in a Tertiary Health Institution

Simple item page
dc.contributor.authorGiwa, A
dc.contributor.authorGiwa, HB
dc.contributor.authorJamiu, M.O
dc.date.accessioned2018-06-11T13:29:51Z
dc.date.available2018-06-11T13:29:51Z
dc.date.issued2018
dc.description.abstractBackground: The increasing health care spending from government, donors and private stand-point has a lot of challenge in health care related decision making. Hence, there is need to examine closely the cost and benefits of drug interventions especially in chronic illnesses like HIV/AIDS. Objective: To conduct cost-effectiveness analysis of combined antiretroviral therapy (cART) in a tertiary health institution Methods: A retrospective review of systematically sampled 360 case notes was conducted. World Health Organization Defined Daily Dose method of evaluating drug use and probability method for potential effectiveness of cART options from literature analysis was employed in determining cost-effectiveness of each option identified from cART drug utilization studies. Results: Zidovudine (AZT )+Lamivudine (3TC) +Nevirapine (NVP)which cost N89 2 ($ 0.3 per unit effectiveness) was more frequently prescribed (86%, =100.82; P=0.00; df=1). This combination was more cost effective than the less frequently prescribed first line option of Tenofovir (TDF) +Lamivudine (3TC) +Efavirenz (EFV)at a cost per unit effectiveness of NGN 134 ($0.45).Similarly, 2 AZT+3TC+Lopinavir/Ritonavir (LPV/r)which was more frequently prescribed (71.4%, =33.62; P=0.00; df=1)]with cost per unit effectiveness of NGN379 ($1.26)was more cost effective than TDF+3TC+LPV/r [NGN403($ 1.34) per unit of effectiveness] in the management of HIV/AIDS patients as second line regimen. Conclusions: AZT+3TC+NVPwas more cost-effective than TDF+3TC+EFV in the management of HIV/AIDS patients as firstline regimen. However, AZT+3TC+LPV/r appeared to, but was not necessarily more cost effective than TDF+3TC+LPV/r in the management of HIV/AIDS patients as second line regimen.en_US
dc.identifier.citationA.Giwa, HB Giwa, MO Jamiu (2018): Cost Effectiveness Analysis of Combined Anti-Retroviral Therapy in a Tertiary Health Institution. West African Journal of Pharmacy, 29(1); 59-69, Published by West African Postgraduate College of Pharmacyen_US
dc.identifier.issn2384-6674
dc.identifier.urihttp://hdl.handle.net/123456789/455
dc.language.isoenen_US
dc.publisherPublished by West African Postgraduate College of Pharmacyen_US
dc.subjectCost-Effectiveness analysis,en_US
dc.subjectcART,en_US
dc.subjectHIV/AIDS,en_US
dc.subjectDefined Daily Doseen_US
dc.titleCost Effectiveness Analysis of Combined Anti-Retroviral Therapy in a Tertiary Health Institutionen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
WAJP GIWA.pdf
Size:
174.88 KB
Format:
Adobe Portable Document Format
Description:
main article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.69 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections